Radiotherapy, Temozolomide and Bevacizumab followed by Irinotecan, Temozolomide and Bevacizumab Appears Well-tolerated and Efficacious in Newly Diagnosed Glioblastoma Multiforme: Results from a Phase II Trial
Publication
, Conference
Kirkpatrick, JP; Desjardins, A; Reardon, DA; Friedman, AH; Friedman, HS; Vredenburgh, JJ
Published in: International Journal of Radiation Oncology*Biology*Physics
November 2009
Duke Scholars
Published In
International Journal of Radiation Oncology*Biology*Physics
DOI
ISSN
0360-3016
Publication Date
November 2009
Volume
75
Issue
3
Start / End Page
S102 / S103
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kirkpatrick, J. P., Desjardins, A., Reardon, D. A., Friedman, A. H., Friedman, H. S., & Vredenburgh, J. J. (2009). Radiotherapy, Temozolomide and Bevacizumab followed by Irinotecan, Temozolomide and Bevacizumab Appears Well-tolerated and Efficacious in Newly Diagnosed Glioblastoma Multiforme: Results from a Phase II Trial. In International Journal of Radiation Oncology*Biology*Physics (Vol. 75, pp. S102–S103). Elsevier BV. https://doi.org/10.1016/j.ijrobp.2009.07.250
Kirkpatrick, J. P., A. Desjardins, D. A. Reardon, A. H. Friedman, H. S. Friedman, and J. J. Vredenburgh. “Radiotherapy, Temozolomide and Bevacizumab followed by Irinotecan, Temozolomide and Bevacizumab Appears Well-tolerated and Efficacious in Newly Diagnosed Glioblastoma Multiforme: Results from a Phase II Trial.” In International Journal of Radiation Oncology*Biology*Physics, 75:S102–3. Elsevier BV, 2009. https://doi.org/10.1016/j.ijrobp.2009.07.250.
Kirkpatrick JP, Desjardins A, Reardon DA, Friedman AH, Friedman HS, Vredenburgh JJ. Radiotherapy, Temozolomide and Bevacizumab followed by Irinotecan, Temozolomide and Bevacizumab Appears Well-tolerated and Efficacious in Newly Diagnosed Glioblastoma Multiforme: Results from a Phase II Trial. In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2009. p. S102–3.
Kirkpatrick, J. P., et al. “Radiotherapy, Temozolomide and Bevacizumab followed by Irinotecan, Temozolomide and Bevacizumab Appears Well-tolerated and Efficacious in Newly Diagnosed Glioblastoma Multiforme: Results from a Phase II Trial.” International Journal of Radiation Oncology*Biology*Physics, vol. 75, no. 3, Elsevier BV, 2009, pp. S102–03. Crossref, doi:10.1016/j.ijrobp.2009.07.250.
Kirkpatrick JP, Desjardins A, Reardon DA, Friedman AH, Friedman HS, Vredenburgh JJ. Radiotherapy, Temozolomide and Bevacizumab followed by Irinotecan, Temozolomide and Bevacizumab Appears Well-tolerated and Efficacious in Newly Diagnosed Glioblastoma Multiforme: Results from a Phase II Trial. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2009. p. S102–S103.
Published In
International Journal of Radiation Oncology*Biology*Physics
DOI
ISSN
0360-3016
Publication Date
November 2009
Volume
75
Issue
3
Start / End Page
S102 / S103
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences